Citations

Clear

941 citation(s) found for "Tefferi, A".

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, Ayalew , Verstovšek, Srđan , Passamonti, Francesco , Gisslinger, Heinz , Paquette, Ronald , Cervantes, Francisco , Rivera, Candido E., Deeg, H. Joachim , Thiele, Jüergen, Kvasnicka, H. M. , Vardiman, James W., Zhang, Yanming , Bekele, B. Nebiyou , Kantarjian, Hagop M. , Barosi, Giovanni , Roboz, Gail J. , Mesa, Ruben A. , Gale, Robert Peter , Verstovsek, Srdan , Passamonti, Francesco , Kantarjian, Hagop

Mayo Clinic

Journal of Clinical Oncology | August 4, 2009 | Volume: 27 | Issue: 27 | Pages: 4563-4569

10.1200/jco.2008.21.7356 | PMID 19652059 Get It

Purpose Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide. Methods In a phase II randomized, multicenter, double-blind, adaptive design study, four treatment arms were evaluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5 mg/d) plus prednisone, and prednisone plus placebo. Pomalidomide was administered for up to 12 28-day treatment cycles. Prednisone (30 mg/d) was given in a tapering dose schedule during the first three cycles. Response was assessed by International Working Group criteria. Results Eighty-four patients with myelofibrosis-associated anemia were randomly assigned to the aforementioned treatment arms: 22, 19, 22, and 21, respectively. Response in anemia was documented in 20 patients, including 15 who became transfusion independent. Response rates in the four treatment arms were 23% (95% CI, 5% to 41%), 16% (95% CI, 0% to 33%), 36% (95% CI, 16% to 56%), and 19% (95% CI, 2% to 36%). The corresponding figures for patients receiving ≥ 3 cycles of treatment (n = 62) were 38%, 23%, 40%, and 25%. Response to pomalidomide with or without prednisone was durable (range, 3.2 to 16.9+ months) and significantly better in the absence of leukocytosis (37% v 8%; P = .01); JAK2V617F or cytogenetic status did not affect response. Grade ≥ 3 toxicities were infrequent and included (in each treatment arm) neutropenia (9%; 16%; 5%; 5%), thrombocytopenia (14%; 16%; 9%; 5%), and thrombosis (9%; 5%; 0%; 0%). Conclusion Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.
Molecular diagnosis of myeloproliferative neoplasms
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

Expert Review of Molecular Diagnostics | July 6, 2009 | Volume: 9 | Issue: 5 | Pages: 481-492

10.1586/erm.09.29 | PMID 19580432 Get It

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Tefferi, Ayalew , Finke, Christy M. , Patnaik, Mrinal M. , Butterfield, Joseph H. , McClure, Rebecca F., Li, Chin‐Yang, Pardanani, Animesh , Lim, Ken‐Hong , Lasho, Terra L. , Li, Chin‐Yang

Mayo Clinic

Blood | April 10, 2009 | Volume: 113 | Issue: 23 | Pages: 5727-5736

10.1182/blood-2009-02-205237 | PMID 19363219 Get It

Abstract Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which complicates prognostication and decision making regarding the choice and timing of therapy. In a retrospective study of 342 consecutive adult patients with SM seen at the Mayo Clinic between 1976 and 2007, disease subdesignation according to the World Health Organization (WHO) proposal was indolent (ISM) in 159 (46%), with associated clonal hematologic non–mast cell lineage disease (SM-AHNMD) in 138 (40%), aggressive (ASM) in 41 (12%), and mast cell leukemia in 4 (1%). KITD816V was detected in bone marrow–derived DNA by allele-specific polymerase chain reaction (PCR) in 68% of 165 patients evaluated (ISM, 78%; ASM, 82%; SM-AHNMD, 60%; P = .03); JAK2V617F was detected in 4%, all in SM-AHNMD. Compared with those with nonindolent SM, life expectancy in ISM was superior and not significantly different from that of the age- and sex-matched US population. In addition, multivariable analysis identified advanced age, weight loss, anemia, thrombocytopenia, hypoalbuminemia, and excess bone marrow blasts as independent adverse prognostic factors for survival. The current study validates the prognostic relevance of the WHO subclassification of SM and provides additional information of value in terms of both risk stratification and interpretation of clinical presentation and laboratory results.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Vardiman, James W., Thiele, Jüergen, Brunning, Richard D., Borowitz, Michael J., Porwit, Anna , Beau, Michelle M. Le , Hellström‐Lindberg, Eva , Tefferi, Ayalew , Bloomfield, Clara D. , Arber, Daniel A. , Harris, Nancy L.

Mayo Clinic

Blood | April 9, 2009 | Volume: 114 | Issue: 5 | Pages: 937-951

10.1182/blood-2009-03-209262 | PMID 19357394 Get It

Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others. It also adds entities—some defined principally by genetic features—that have only recently been characterized. In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Gery, Sigal, Cao, Qi , Gueller, Saskia, Xing, Hongtao, Tefferi, Ayalew , Koeffler, H. Phillip

Mayo Clinic

Journal of Leukocyte Biology | March 18, 2009 | Volume: 85 | Issue: 6 | Pages: 957-965

10.1189/jlb.0908575 | PMID 19293402 Get It

AbstractThe JAK2 mutation JAK2V617F is found frequently in patients with myeloproliferative disorders (MPD) and transforms hematopoietic cells to cytokine-independent proliferation when expressed with specific cytokine receptors. The Src homology 2 (SH2) and pleckstrin homology (PH) domain-containing adaptor protein Lnk (SH2B3) is a negative regulator of hematopoietic cytokine signaling. Here, we show that Lnk is a potent inhibitor of JAK2V617F constitutive activity. Lnk down-regulates JAK2V617F-mediated signaling and transformation in hematopoietic Ba/F3-erythropoietin receptor cells. Furthermore, in CFU assays, Lnk-deficient murine bone marrow cells are significantly more sensitive to transformation by JAK2V617F than wild-type (WT) cells. Lnk, through its SH2 and PH domains, interacts with WT and mutant JAK2 and is phosphorylated by constitutively activated JAK2V617F. Finally, we found that Lnk levels are high in CD34+ hematopoietic progenitors from MPD patients and that Lnk expression is induced following JAK2 activation. Our data suggest that JAK2V617F is susceptible to endogenous negative-feedback regulation, providing new insights into the molecular pathogenesis of MPD.
Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Verstovšek, Srđan , Tefferi, Ayalew , Kantarjian, Hagop M. , Manshouri, Taghi, Luthra, Raja, Pardanani, Animesh , Quintás‐Cardama, Alfonso , Ault, Pat, Bueso‐Ramos, Carlos E. , Cortes, Jörge E. , Ravandi, Farhad , Cortes, Jorge , Verstovsek, Srdan , Kantarjian, Hagop

Mayo Clinic

Clinical Cancer Research | December 31, 2008 | Volume: 15 | Issue: 1 | Pages: 368-373

10.1158/1078-0432.ccr-08-1302 | PMID 19118067 Get It

Abstract Purpose: Patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that are refractory to standard therapies are difficult to manage and have significantly shortened life expectancy. Experimental Design: CD52 is a surface glycoprotein highly expressed on eosinophils. We treated 11 patients with advanced HES/CEL with alemtuzumab, a humanized anti-CD52 monoclonal antibody. Alemtuzumab was administered, in general, first in escalating doses (5, 10, 30 mg i.v. on days 1-3), then at the tolerated dose thrice per week for a total of 12 doses. Patients with complete hematologic response (CHR; normal percent and absolute eosinophil count) were allowed to continue therapy once weekly as maintenance. Results: Ten patients (91%) achieved CHR after a median of 2 weeks (0.5-5 weeks) of therapy. Bone marrow eosinophilia resolved in four of seven evaluable patients. The median duration of CHR was 3 months (1.5-17+ months). Seven of the 10 CHR patients relapsed, five while off-therapy. Two patients achieved second CHR upon alemtuzumab rechallenge. Three patients experienced mild infusion-related symptoms, two developed cytomegalovirus reactivation requiring therapy, and one developed orbital lymphoma that was successfully treated. Conclusions: Our limited experience suggests alemtuzumab to be a valuable therapy for advanced HES or CEL, refractory to standard therapies, and supports the clinical evaluation of alemtuzumab in a larger trial.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Cervantes, Francisco , Dupriez, Brigitte, Pereira, Arturo , Passamonti, Francesco , Reilly, John T., Morra, Enrica, Demory, Jean‐Loup, Rumi, Elisa , Tefferi, Ayalew , Vannucchi, Alessandro M. , Mesa, Ruben A. , Barosi, Giovanni , Passamonti, Francesco

Mayo Clinic

Blood | November 6, 2008 | Volume: 113 | Issue: 13 | Pages: 2895-2901

10.1182/blood-2008-07-170449 | PMID 18988864 Get It

Abstract Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivariate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 109/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P < .001). Compared with prior prognostic models, the new risk stratification system displayed higher predictive accuracy, replicability, and discriminating power. In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups. JAK2V617F did not cluster with a specific risk group or affect survival.
Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Verstovšek, Srđan , Tefferi, Ayalew , Cortes, Jörge E. , O’Brien, Susan , Garcia‐Manero, Guillermo , Pardanani, Animesh , Akin, Cem , Faderl, Stefan, Manshouri, Taghi , Thomas, Deborah A. , Kantarjian, Hagop M. , Cortes, Jorge , Verstovsek, Srdan , Akin, Cem , Kantarjian, Hagop

Mayo Clinic

Clinical Cancer Research | June 16, 2008 | Volume: 14 | Issue: 12 | Pages: 3906-3915

10.1158/1078-0432.ccr-08-0366 | PMID 18559612 Get It

Abstract Purpose: Molecular characterization of Philadelphia chromosome–negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor β TKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph− myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Pardanani, Animesh , Gilliland, D. Gary, Tefferi, Ayalew , Fridley, Brooke L. , Lasho, Terra L.

Mayo Clinic

Blood | November 16, 2007 | Volume: 111 | Issue: 5 | Pages: 2785-2789

10.1182/blood-2007-06-095703 | PMID 18006699 Get It

JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We tested the hypothesis that the paradox of a single disease allele associated with 3 distinctive clinical phenotypes could be explained in part by host-modifying influences. We screened for genetic variation within 4 candidate genes involved in JAK-STAT signaling, including receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating factor (GCSFR), and JAK2. We genotyped 32 linkage disequilibrium tag single nucleotide polymorphism (SNP) loci in 179 white patients: 84 had PV, 58 had PMF, and 37 had ET. Genotype-phenotype analysis showed 3 JAK2 SNPs (rs7046736, rs10815148, and rs12342421) to be significantly but reciprocally associated with PV (P < .001 for all; odds ratio = 0.16, 2.72, and 2.46, respectively) and ET (P < .001 for all; odds ratio = 3.05, 0.29, and 0.30, respectively) but not with PMF. Three additional JAK2 SNPs (rs10758669, rs3808850, and rs10974947) and a single EPOR SNP (rs318699) were also significantly associated with PV but not with ET or PMF. Finally, intragene haplotypes in JAK2 were significantly associated with PV only. Thus, host genetic variation may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence of a shared disease allele.
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival
Elliott, Michelle A. , Litzow, Mark R. , Letendre, Louis, Hanson, Curtis A. , Tefferi, Ayalew , Tallman, Martin S. , Wolf, Robert Christian

Mayo Clinic

Blood | October 2, 2007 | Volume: 110 | Issue: 13 | Pages: 4172-4174

10.1182/blood-2007-07-104091 | PMID 17909077 Get It

In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.